A sample brief. This is the Obesity watchlist’s brief for the week to Nov 15, 2026, from the registry’s real records. Yours comes every Monday for the conditions, companies and programs you add.

Obesity

Weekly Watchlist Brief · week to Nov 15, 2026

Amgen opened a 230-person phase 3 of maridebart cafraglutide

15 changes · 175 programs · 85 companies · 17 phase-3 readouts in the next 6 months

Every change

Ranked as the email ranks them: phase 3 first, then by kind and study size. Each study links to its page.

Kind	Program	What changed	Studies
Opened	Maridebart cafraglutide Amgen	Phase 3 opened 230 participants (planned) · 2 countries	NCT07871409
Opened	Bofanglutide Gan & Lee Pharmaceuticals	Phase 3 opened 140 participants (planned) · 1 country	NCT07493057
Registered	Berobenatide Pfizer	New phase 3 registered 900 participants (planned)	NCT07932925
Completed	Bofanglutide Gan & Lee Pharmaceuticals	2 phase 3 studies completed −12 months · Sep 2027 → Sep 22, 2026 · 224 enrolled (500 planned) · 1 country	NCT07292441 NCT06728124
Enrollment	Zenagamtide Novo Nordisk A/S	Phase 3 fully enrolled 985 enrolled (1,000 planned) · 14 countries	NCT07400107
Date	Retatrutide Eli Lilly and Company	Phase 3 primary completion moved earlier −1 month · Jul 2027 → Jun 2027 · 250 participants (planned) · 2 countries	NCT07232719
Opened	Olatorepatide Regeneron Pharmaceuticals	Phase 2 opened 300 participants (planned) · 1 country	NCT07830329
Registered	Ecnoglutide Hangzhou Sciwind Biosciences Co., Ltd.	New phase 2 registered 180 participants (planned) · 1 country	NCT07929298
Completed	Garetosmab Regeneron Pharmaceuticals	Phase 2 completed 1,005 participants · 2 countries	NCT06299098
Opened	Zenagamtide Novo Nordisk A/S	Phase 1 opened 35 participants (planned) · 1 country	NCT07587710
Registered	NKS-3 EktaH	New phase 1 registered 120 participants · 1 country	NCT07924267
Registered	KAI-4729 Kailera	New phase 1 registered 60 participants (planned) · 1 country	NCT07924761
Completed	Bofanglutide Gan & Lee Pharmaceuticals	4 phase 1 studies completed −3 months · Jul 5, 2026 → Apr 13, 2026 · 60 participants · 1 country	NCT07128888 NCT07141030 NCT07355738 NCT07144098
Completed	BGM1812 BrightGene Bio-Medical Technology Co., Ltd.	Phase 1 completed 60 participants · 1 country	NCT07224399
Date	Elecoglipron AstraZeneca	Phase 1 primary completion moved later +4 months · Oct 1, 2026 → Jan 25, 2027 · 48 participants · 1 country	NCT07534592

Pipeline by highest phase

175 programs from 85 companies

Early 1 · 3Phase 1 · 70Phase 2 · 60Phase 3 · 39Phase 4 · 3

Readouts ahead

Phase-3 primary completions in the next 6 months, as the registry estimates them

Nov 2026Retatrutide (Eli Lilly) · 800; Tirzepatide (Eli Lilly) · 2 studies
Dec 2026Ribupatide (Jiangsu HengRui Medicine) · 2 studies; IN-B00009 (HK inno.N) · 300
Jan 2027Maridebart cafraglutide (Amgen) · 2 studies
Feb 2027Orforglipron (Eli Lilly) · 125; Tirzepatide (Hudson Biotech) · 2,539
Mar 2027Ribupatide (Jiangsu HengRui Medicine) · 572; Cagrilintide (Novo Nordisk) · 609
May 2027Mazdutide (Innovent Biologics) · 260; Cagrilintide (Novo Nordisk) · 3 studies; ZT002 (Beijing QL Biopharmaceutical) · 755

Start your own

Add a condition or a company to your watchlists, or track single programs. Each brief can be exported as CSV (Pro, free during the beta).

Add Obesity to watchlist

Programs come from the registry’s company-led studies of the last two years. A program’s phase is the highest its studies have reached. Dates are the registry’s estimates unless marked actual.